{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:42:33Z","timestamp":1793270553211,"version":"4.5.0"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","award":["201700677"],"award-info":[{"award-number":["201700677"]}],"id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>In dogs with non-resectable hepatic neoplasia, treatment options are limited. The objectives of this study were to describe the use of a novel drug-eluting embolic microsphere containing paclitaxel for use during transarterial chemoembolization (TACE), to compare results of liver-specific owner questionnaires and tumor volume pre- and post-TACE, and to measure systemic paclitaxel concentration post-TACE. Client-owned dogs with non-resectable hepatic neoplasia were prospectively enrolled. All owners completed questionnaires validated for the assessment of subjective outcomes in dogs with cancer before the TACE procedure and approximately 4 weeks after the TACE procedure. A CT scan was performed before TACE and 1 month after TACE; results were compared. Blood samples were obtained at specified time points post-TACE to determine systemic paclitaxel concentrations. Seven dogs (median weight: 8.9 kg; range, 4.3\u201331 kg) were enrolled. TACE was successfully performed in all dogs, and no intra-procedural complications were encountered. Questionnaire scores improved significantly post-TACE. Among the 6 dogs for which full data were available, median pre-TACE tumor volume was 390 cc (range 152\u20131,484; interquartile range 231\u20131,139) and median post-TACE tumor volume was 203 cc (range 98\u2013889; interquartile range 151\u2013369), which was significantly (P = .028) lower. All 6 dogs had a reduction in volume at the post-TACE measurement. Mean percent change in tumor volume was -45.6% (95%CI -58.6 to -32.6%). The mean plasma paclitaxel concentration in canine blood peaked at 4 days post-TACE procedure and was 25.7 ng\/mL (range = 3.09\u2013110 ng\/mL) Median survival time was 629 days (95%CI 18 to upper limit not reached). The use of a novel paclitaxel-eluting microsphere in this cohort of dogs successfully decreased tumor volume significantly after TACE and improved clinical signs. Future investigation into the use of TACE and other similar therapies is warranted due to the promising outcomes noted in this cohort.<\/jats:p>","DOI":"10.1371\/journal.pone.0269941","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T17:31:24Z","timestamp":1659979884000},"page":"e0269941","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of the use of a novel bioabsorbable polymer drug-eluting microsphere for transarterial embolization of hepatocellular neoplasia in dogs"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6132-156X","authenticated-orcid":true,"given":"William T. N.","family":"Culp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-3494","authenticated-orcid":true,"given":"Robert B.","family":"Rebhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Cawthra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi A.","family":"Schwanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1895-8298","authenticated-orcid":true,"given":"Jenna H.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"pone.0269941.ref001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/030098588101800402","article-title":"Canine hepatocellular carcinoma","volume":"18","author":"AK Patnaik","year":"1981","journal-title":"Vet Pathol"},{"key":"pone.0269941.ref002","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2460\/javma.2004.225.1225","article-title":"Massive hepatocellular carcinoma in dogs: 48 cases (1992\u20132002)","volume":"225","author":"JM Liptak","year":"2004","journal-title":"J Am Vet Med Assoc"},{"key":"pone.0269941.ref003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5493\/wjem.v6.i1.21","article-title":"Hepatocellular carcinoma: Where are we?","volume":"6","author":"R Mazzanti","year":"2016","journal-title":"World J Exp Med"},{"key":"pone.0269941.ref004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.7314\/APJCP.2016.17.2.473","article-title":"Transarterial therapies for hepatocellular carcinoma: a comprehensive review with current updates and future directions","volume":"17","author":"Y Kumar","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"pone.0269941.ref005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data","volume":"64","author":"R Lencioni","year":"2016","journal-title":"Hepatology"},{"key":"pone.0269941.ref006","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00261-016-0639-5","article-title":"Hepatic imaging following intra-arterial embolotherapy","volume":"41","author":"JR Kallini","year":"2016","journal-title":"Abdom Radiol"},{"key":"pone.0269941.ref007","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/vsu.13279","article-title":"A systematic review of criteria used to report complications in soft tissue and oncologic surgical clinical research studies in dogs and cats","volume":"49","author":"CM Follette","year":"2020","journal-title":"Vet Surg"},{"key":"pone.0269941.ref008","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/vco.283","article-title":"Veterinary cooperative oncology group\u2014common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2016","journal-title":"Vet Comp Oncol"},{"key":"pone.0269941.ref009","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jvir.2017.04.025","article-title":"Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy","volume":"28","author":"RC Gaba","year":"2017","journal-title":"J Vasc Interv Radiol"},{"key":"pone.0269941.ref010","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"C Breedis","year":"1954","journal-title":"Am J Pathol"},{"key":"pone.0269941.ref011","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/SLA.0b013e3181961c16","article-title":"A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma","volume":"249","author":"WP Zhou","year":"2009","journal-title":"Ann Surg"},{"key":"pone.0269941.ref012","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1476-5810.2003.00028.x","article-title":"Treatment of unresectable hepatocellular adenoma in dogs with transarterial iodized oil and chemotherapy with and without an embolic agent: a report of two cases","volume":"1","author":"TA Cave","year":"2003","journal-title":"Vet Comp Oncol"},{"key":"pone.0269941.ref013","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2460\/javma.2002.221.1430","article-title":"Percutaneous arterial embolization and chemoembolization for treatment of benign and malignant tumors in three dogs and a goat","volume":"221","author":"C Weisse","year":"2002","journal-title":"J Am Vet Med Assoc"},{"key":"pone.0269941.ref014","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/jsap.12944","article-title":"Transcatheter arterial embolisation in four dogs with hepatocellular carcinoma","volume":"60","author":"Y Oishi","year":"2019","journal-title":"J Small Anim Pract"},{"key":"pone.0269941.ref015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1292\/jvms.21-0396","article-title":"Effect of drug-eluting bead transarterial chemoembolization loaded with cisplatin on normal dogs","volume":"84","author":"K Nakasumi","year":"2022","journal-title":"J Vet Med Sci"},{"key":"pone.0269941.ref016","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/jvim.16109","article-title":"Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: a prospective clinical trial","volume":"35","author":"CP Rogatko","year":"2021","journal-title":"J Vet Intern Med"},{"key":"pone.0269941.ref017","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jhep.2015.02.010","article-title":"Transarterial chemoembolization: modalities, indication, and patient selection","volume":"62","author":"W Sieghart","year":"2015","journal-title":"J Hepatol"},{"key":"pone.0269941.ref018","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jvim.12596","article-title":"A review of paclitaxel and novel formulations including those suitable for use in dogs","volume":"29","author":"C Khanna","year":"2015","journal-title":"J Vet Intern Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T17:31:43Z","timestamp":1659979903000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269941"}},"subtitle":[],"editor":[{"given":"Douglas H.","family":"Thamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0269941","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]}}}